Middle East and Asia Pacific Cell and Gene Therapy Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others), by Technology (Lentiviral Vector, Plasmid DNA, and AAV), and by Region (Middle East and Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Cell therapy is the administration of living cells in patients for the treatment of a disease such as oncology, Immunology and others. The source of a cell can be autologous or allogeneic, which can be derived from stem cells such as bone marrow. Stem cells therapy is used in bone marrow transplantation. Gene therapy is the introduction, removal, or change in the patient's genetic code for the treatment of a disease. Moreover, it modifies the expression of an individual’s genes or repairs abnormal genes. The therapy involves the administration of nucleic acid (DNA/RNA) with carriers called vectors.
Market Dynamics
Key players are focusing on product approvals and launches to strengthen their position in the Middle East and Asia Pacific cell and gene therapy market. For instance, in March 2021, Novartis received Singapore Health Sciences Authority (HSA) approval for Kymriah (tisagenlecleucel), as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue, and gene therapy products (CTGTP) regulatory framework.
Furthermore, in February 2021, the commercial manufacturing of Novartis’s Kymriah was approved by Therapeutic Goods Administration (TGA) in Australia.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook